Children with CKD have a significant burden, including fatigue and sleep disturbances.

Published Date: 13 Mar 2023

A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...

Read Full News

Latest News

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

CAR T-Cell Therapy Enabled Kidney Transplant in Highly Sensitized Patients

Strategy offers hope for hard-to-match patients

Todays Updates

Buprenorphine XR Injections Cut 'Need-Based' Opioid Craving

Extended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.

Fatty Pancreas Linked to Risk for T2D and CKD

Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.

Todays Updates

Buprenorphine XR Injections Cut 'Need-Based' Opioid Craving

Extended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.

Fatty Pancreas Linked to Risk for T2D and CKD

Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.

Latest News

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Strategy offers hope for hard-to-match patients

News All Time

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Kidney Cancer: Current Treatment Approaches Using Targeted Agents and Immunotherapy

Kidney Cancer: Current Treatment Approaches Using Targeted Agents and Immunotherapy

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Recommended News For You

novel technique for early myelodysplastic syndrome relapse detection in blood cancer patients.

When it comes to obesity-related cancers, where you shop for food matters

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.

Immunotherapy Remains Little Used in Head and Neck Cancer

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

Recommended Articles For You

Cancer Rates on the Rise: What Can We Do to Stop It? 

Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers 

Comprehensive Applications in Oncology and Quality Improvement 

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Combination Treatment May Improve Multiple Myeloma Outcomes

2.

To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.

3.

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

4.

Mortality up for children with leukemia from lowest SES neighborhoods

5.

WHO launches plan for free child cancer medicines

1.

Autophagy: A Double-Edged Sword in Cancer Development, Immune Evasion, and Drug Resistance

2.

Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy

3.

Evidence-Based Pathways for Survivorship Care Planning

4.

Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial

5.

The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Navigating the Complexities of Ph Negative ALL - Part XIV

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

4.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases

5.

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot